New Zealand markets closed

Takeda Pharmaceutical Company Limited (TAK)

NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
14.07+0.05 (+0.36%)
At close: 4:00PM EDT
Currency in USD

Valuation measures

Market cap (intra-day) 544.24B
Enterprise value 376.93B
Trailing P/E 11.76
Forward P/E 18.78
PEG ratio (5-yr expected) 10.12
Price/sales (ttm)1.52
Price/book (mrq)0.97
Enterprise value/revenue 30.02
Enterprise value/EBITDA 70.07

Trading information

Stock price history

Beta (5Y monthly) 1.10
52-week change 3-15.14%
S&P500 52-week change 333.64%
52-week high 319.97
52-week low 313.91
50-day moving average 315.81
200-day moving average 316.60

Share statistics

Avg vol (3-month) 32.2M
Avg vol (10-day) 32.33M
Shares outstanding 53.15B
Implied shares outstanding 6N/A
Float 83.14B
% held by insiders 10.01%
% held by institutions 13.07%
Shares short (29 Sep 2021) 46.51M
Short ratio (29 Sep 2021) 43.77
Short % of float (29 Sep 2021) 4N/A
Short % of shares outstanding (29 Sep 2021) 40.21%
Shares short (prior month 30 Aug 2021) 45.81M

Dividends & splits

Forward annual dividend rate 40.84
Forward annual dividend yield 45.95%
Trailing annual dividend rate 3180.00
Trailing annual dividend yield 31,283.88%
5-year average dividend yield 44.14
Payout ratio 466.02%
Dividend date 314 Dec 2009
Ex-dividend date 429 Mar 2021
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Currency in JPY.

Fiscal year

Fiscal year ends 30 Mar 2021
Most-recent quarter (mrq)29 Jun 2021

Profitability

Profit margin 12.89%
Operating margin (ttm)16.04%

Management effectiveness

Return on assets (ttm)2.65%
Return on equity (ttm)8.69%

Income statement

Revenue (ttm)3.35T
Revenue per share (ttm)1,069.84
Quarterly revenue growth (yoy)18.40%
Gross profit (ttm)2.2T
EBITDA 1.03T
Net income avi to common (ttm)431.18B
Diluted EPS (ttm)1.21
Quarterly earnings growth (yoy)66.90%

Balance sheet

Total cash (mrq)684.85B
Total cash per share (mrq)217.75
Total debt (mrq)4.41T
Total debt/equity (mrq)84.10
Current ratio (mrq)1.45
Book value per share (mrq)1,665.55

Cash flow statement

Operating cash flow (ttm)1.03T
Levered free cash flow (ttm)913.05B